Abstract: The invention relates to novel substituted 1,3,5-triazines of the general formula (I) in which A represents CHR3R4 or represents C1-halogenoalkyl-substituted C3-C6-cycloalkyl, C3-C6-alkinyl or C1-C4-cyanoalkyl, where R1, R2, R3 and R4 are each as defined in the description, and to processes for their preparation, to novel intermediates, including their preparation, and to the use of the compounds of the general formula (I) as herbicides.

Abstract: The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.

Abstract: The invention relates to novel substituted N-aryl nitrogen-containing heterocyclic compounds of the general formula (I) 1

Abstract: This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein —a1═a2—a3═a4— forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl or substituted C1-6alkyl; each R2 independently is hydroxy, halo, optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl, C3-7cycloalkyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR4, —NH—S(═O)pR4, —C(═O)R4, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R4, —C(═NH)R4 or a 5-membered heterocyclic ring; p is 1 or 2; L is optionally substituted C1-10alkyl, C2-10alk

Abstract: This invention provides novel pyrazole compounds that are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3. The compounds may be used to treat abnormal physiological function leading to diseases such as cancer, diabetes and Alzheimer's disease.

Abstract: A serotonin reuptake inhibitor containing a cyclic amine represented by the following formula, a prodrug thereof, or a pharmaceutically acceptable salt of said cyclic amine or prodrug as an active ingredient: 1

Abstract: Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, circadian rhythm disorders, ocular disorders and/or centrally and peripherally mediated hypertension are provided.

Abstract: Invented are G-CSF mimetics. Also invented are selected octacyclic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds as G-CSF mimetics. Also invented are novel processes used in preparing these compounds.

Abstract: Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor cells.

Abstract: Compounds that selectively inhibit inappropriate kinase activities and methods for their preparation are disclosed.

Abstract: A compound of formula (I) wherein n is e.g. a number from 2 to 50; R5′ and R5″ are e.g. a group of formula (II); G1, G2, G3 and G4 are e.g. C1-C4akyl; R1 is e.g. hydrogen or C1-C4alkyl; R2 is e.g. methylene; R3′ is e.g. hydrogen and R3″ is e.g. hydrogen or C1-C4alkyl; R4 is e.g. C2-C8alkylene; and X is e.g. —N(R7)R8) with R7 and R8 being independently of one another hydrogen or C1-C8alkyl, is useful for stabilizing an organic material against degradation induced by light, heat or oxidation.

Abstract: The present invention describes novel isoxazolo[1,5-a]pyrimidines of formula: 1

Abstract: A pyrimidinylbenzimidazole or triazinylbenzimidazole derivative represented by the general formula (I): wherein A is N or CR3, and R1, R2, R3, X, Y and n are as defined in the disclosure.

Abstract: This invention is directed to triazine derivatives which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Abstract: The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer and angiogenesis-related disease.

Abstract: N-Heterocyclic derivatives of the formula (I): 1

Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with indoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

Abstract: N-Heterocyclic derivatives of the formula (I): 1

Abstract: Disclosed are compositions for printing recording materials, especially textile fibre materials, paper and papery substrates and plastic films and plastic transparencies by the inkjet printing process, including

Abstract: N-Heterocyclic derivatives of the formula (I): 1

Abstract: This invention describes novel pyrazole compounds of formula II: 1

Abstract: The present invention describes novel pyrazolo[1,5-a]triazines of formula: wherein R3 is an alkyl, alkenyl, alkynyl, or cycloalkyl group, or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.

Abstract: This invention is directed to sorbitol dehydrogenase inhibitory compounds of formula I 1

Abstract: A product obtainable by 1) reacting a compound of the formula (&agr;) with a compound of the formula (&bgr;) in a molar ratio of 1.2:1 to 1.4:1; 2) reacting the end groups of the formula (&ggr;) being present in the product of the reaction 1) with e.g. dibutylamine in a molar ratio of 2:1.7 to 2:3; the reactions 1) and 2) being carried out in an organic solvent in the presence of an inorganic base; and 3) transferring the groups of the formula being present in the product of the reaction 2) to groups of the formula said transfer being carried out by reacting the product of the reaction 2) with a hydroperoxide in a hydrocarbon solvent in the presence of a peroxide decomposing catalyst. The products obtained are useful as light stabilizers, heat stabilizers and oxidation stabilizers for organic materials, in particular synthetic polymers such as polyolefins.

Abstract: N-Heterocyclic derivatives of the formula (I): 1

Abstract: This invention relates to novel heterocycles which are useful as antagonists of the &agr;v&bgr;3 integrin, the &agr;2b&bgr;3 integrin, and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Abstract: N-Heterocyclic derivatives of the formula (I): 1

Abstract: The present invention relates to novel N-cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

Abstract: The present invention relates to ester, ether and N-alkylcarbamoyl derivatives of compound (Ia) and pharmaceutically acceptable salts thereof. These compounds exhibit excellent antibacterial activity and are useful for the treatment or prevention of bacterial infections. (wherein R1 is a hydrogen atom or a methyl group; R2a is a hydrogen atom, a protecting group for a hydroxy group, or a methyl group; R3 is a hydrogen atom or a protecting group for a hydroxy group; R4a is a hydrogen atom, a hydroxy group or a protected hydroxy group; R5 is a hydrogen atom or a protecting group for a hydroxy group; and X is a methylene group or a sulfur atom). The invention also includes compounds which are related to the aforeidentified compounds.

Abstract: Polyaminotriazines represented by formula (I) can be prepared by conducting a reduction alkylamination of a tetramethylpiperidone with a diamine represented by formula (IIb), NH2—R—NH2, in the presence of a hydrogenating catalyst, removing the catalyst upon completion of the reaction to obtain an unrefined crude product (A); and, conducting a polycondensation reaction of the unrefined crude product (A) and a dichlorotriazine in an aromatic solvent and in the presence of an inorganic base.

Abstract: Hindered amine compounds which are substituted by a long hydrocarbon chain are useful in a number of applications where the solubility or compatibility afforded by said substitution is needed. This is seen particularly for example with white, dyed, dipped, unscented and/or scented candle wax which is effectively stabilized against discoloration and fading by the incorporation therein of a long chain hindered amine alone or in combination with a UV absorber and/or an antioxidant.

Abstract: This invention concerns the compounds of formula 1

Abstract: The invention related to novel substituted arylsulphonyl(thio)ureas wherein: A is nitrogen or a CH grouping, Q is oxygen or sulphur, R1 is hydrogen, halogen or optionally substituted alkyl, alkoxy, alkylthio, alkylamino, dialkylamino, cycloalkyl, cycloalkyloxy or heterocyclyloxy, R2 is hydrogen, halogen or optionally substituted alkyl, alkoxy, alkylthio, alkylamino, dialkylamino, cycloalkyl, cycloalkyloxy or heterocyclyloxy, R3 is hydrogen or optionally substituted alkyl, R4 is optionally substituted alkyl, alkoxy, alkenyl, alkinyl, alkenyloxy, alkinyloxy, cycloalkyl, cycloalkyloxy or cycloalkylalkyl, and R5 is hydrogen, formyl or optionally substituted alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulphonyl, alkenyl, alkinyl, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulphonyl or heterocyclyl, and salts of compounds of the formula (I), except for the compound N-(4,6-dimethyl-pyrimidin-2-yl)-N′-[2-(1,1,2,2-tetrafluoro-ethoxy)-6-methyl-phenylsulphonyl]-urea.

Abstract: Compounds of formula I wherein G, J, L, M, m and D have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Abstract: A product containing 5 to 85% of a group (A-1-a) and/or (A-1-b) and 15 to 95% of a group (A-2), the total sum of the groups (A-1-a), (A-1-b) and (A-2) being 100%, is useful for stabilizing an organic material against degradation induced by light, heat or oxidation.

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&bgr; activity.

Abstract: This invention is directed to triazine derivatives which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

Abstract: The invention relates to novel thienylalkylamino-1,3,5-triazines of the general formula (I) in which A, R1, R2, R3, R4, R5 and Z are as defined in the description, to processes for their preparation, to their use as herbicides and to novel intermediates and their preparation.

Abstract: A product obtainable by transferring groups of formula (G-I) being present in a block oligomer having a polydispersity {overscore (M)}w/{overscore (M)}n of 1 to 1.7 and corresponding to formula (I) to groups of formula (Gu-II), wherein R1 is a hydrocarbyl radical or —O—R1 is oxyl; said transfer is carried out by reaction of the block oligomer with a hydroperoxide in a hydrocarbon solvent in the presence of a peroxide decomposing catalyst; n is a number from 2 to 14; R2 is for example C2-C12alkylene; A is for example —N(R4)(R5); R4 and R5 are for example C1-C18alkyl; R is preferably a group of formula (G-I) and B and B* have one of the meanings given for A; with the proviso that in the individual recurrent units of formula (I), each of the radicals B, R and R2 has the same or a different meaning. The products are useful as light stabilizers, heat stabilizers and oxidation stabilizers for organic materials, in particular synthetic polymers.

Abstract: The invention relaters to compounds of the formula: and their use as herbicides.

Abstract: A product obtained by 1) reacting a compound of the formula (&agr;) with a compound of the formula (&bgr;) in a stoichiometric ratio to obtain a compound of the formula (&ggr;) 2) reacting the compound of the formula (&bgr;) with the compound of the formula (&ggr;) in a molar ratio of 0.4:1 to 0.75:1; 3) reacting the end groups of the formula (&dgr;) being present in the product of the reaction 2) with e.g. dibutylamine in a molar ratio of 2:1.7 to 2:3; the reactions 1) to 3) being carried out in an organic solvent in the presence of an inorganic base; and 4) transferring the groups of the formula being present in the product of the reaction 3) to groups of the formula said transfer being carried out by reacting the product of the reaction 3) with a hydroperoxide in a hydrocarbon solvent in the presence of a peroxide decomposing catalyst; R1 is in particular a hydrocarbyl radical, B is e.g.

Abstract: There are described cycloalkyl derivatives of the formula (I) R1—Y—A—B—D—E—F—G  (I) in which R1, Y, A, B, D, E, F and G have the meaning indicated herein, their preparation and their use as medicaments. The compounds according to the invention can be used as vitronectin receptor antagonists and as inhibitors of bone resorption.

Abstract: Hindered amines substituted on the N-atom with an —O—E—OH moiety are particularly effective in stabilizing polyolefin and automotive coating compositions against the deleterious effects of oxidative, thermal and actinic radiation where the presence of the OH group on the compounds adds important properties not attainable by the use of normal —O—E moieties.

Abstract: The invention relates to a compound of formula (I) which can inhibit the production of IL-12. Also disclosed is a method of inhibiting IL-12 production by administering to a patient in need thereof an effective amount of a compound of formula (I).

Abstract: A compound of the formula: 1

Abstract: This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR4 or N; n is 0, 1, 2, 3 or 4; R1 and R2 are each independently selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each of the aforementioned C1-12alkyl groups may optionally and each individually be substituted; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4alkylidene; R3 is hydrogen, aryl, C1-6alkylcarbonyl, optionally substituted C1-6alkyl; and each R4 independently is hydroxy, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is —X—R5 or —X-Alk-R6; wherein R5 and R6 each independently are indanyl, indolyl or phenyl; each of

Abstract: The present invention provides methods of correlating genetic variants in the beta-chemokine receptor 5 (CCR5) locus, more specifically CCR5 promoter alleles and genotypes, with HIV-1 transmission and/or disease progression in individuals and populations.

Abstract: Disclosed are compounds of the formula: where R1, R2, R3, R4, R5, R6, and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.

Abstract: The invention relates to novel substituted 2-amino-4-alkylamino-1,3,5-triazines of the formula (I) in which R1 represents in each case optionally substituted alkyl having 2 to 6 carbon atoms or cycloalkyl having 3 to 6 carbon atoms, R2 represents hydrogen or represents alkyl having 1 to 4 carbon atoms, A represents oxygen or methylene, Ar represents in each case optionally substituted phenyl, naphthyl or heterocyclyl, and Z represents hydrogen, represents halogen or represents in each case optionally substituted alkyl, alkoxy, alkylcarboxyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, alkenyl or alkinyl, to processes and to novel intermediates for their preparation and to their use as herbicides.